Pulmonx Analyst Ratings
Pulmonx Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/31/2023 | 35.59% | Canaccord Genuity | $20 → $12 | Maintains | Buy |
| 09/05/2023 | 103.39% | Craig-Hallum | → $18 | Initiates Coverage On | → Buy |
| 08/03/2023 | 92.09% | Piper Sandler | $15 → $17 | Maintains | Overweight |
| 07/11/2023 | 80.79% | Citigroup | $14 → $16 | Maintains | Buy |
| 05/03/2023 | 58.19% | Citigroup | $13 → $14 | Maintains | Buy |
| 05/03/2023 | 69.49% | Piper Sandler | $13 → $15 | Maintains | Overweight |
| 05/03/2023 | 58.19% | Morgan Stanley | $11 → $14 | Maintains | Equal-Weight |
| 04/03/2023 | 46.89% | Citigroup | $12 → $13 | Maintains | Buy |
| 02/27/2023 | 69.49% | Wells Fargo | $10 → $15 | Upgrades | Equal-Weight → Overweight |
| 02/24/2023 | 35.59% | Citigroup | $10 → $12 | Maintains | Buy |
| 02/23/2023 | 125.99% | Canaccord Genuity | $18 → $20 | Maintains | Buy |
| 02/23/2023 | 24.29% | Morgan Stanley | $9.5 → $11 | Maintains | Equal-Weight |
| 01/06/2023 | 7.34% | Morgan Stanley | $14 → $9.5 | Maintains | Equal-Weight |
| 01/03/2023 | -9.6% | B of A Securities | → $8 | Downgrades | Neutral → Underperform |
| 12/12/2022 | -32.2% | Wells Fargo | $13.5 → $6 | Maintains | Equal-Weight |
| 12/12/2022 | 12.99% | Citigroup | $14 → $10 | Upgrades | Neutral → Buy |
| 11/07/2022 | 58.19% | Morgan Stanley | $19 → $14 | Maintains | Equal-Weight |
| 11/04/2022 | 46.89% | Piper Sandler | $25 → $13 | Maintains | Overweight |
| 10/11/2022 | 114.69% | Morgan Stanley | $21 → $19 | Maintains | Equal-Weight |
| 08/04/2022 | 137.29% | Morgan Stanley | $19 → $21 | Maintains | Equal-Weight |
| 08/03/2022 | 182.49% | Piper Sandler | $37 → $25 | Maintains | Overweight |
| 07/18/2022 | 125.99% | Stifel | $32 → $20 | Maintains | Buy |
| 07/15/2022 | 114.69% | Morgan Stanley | $30 → $19 | Maintains | Equal-Weight |
| 07/11/2022 | 114.69% | Citigroup | $23 → $19 | Downgrades | Buy → Neutral |
| 05/17/2022 | 159.89% | Citigroup | $32 → $23 | Maintains | Buy |
| 02/25/2022 | 238.98% | Morgan Stanley | $37 → $30 | Maintains | Equal-Weight |
| 02/24/2022 | 205.08% | Wells Fargo | $55 → $27 | Maintains | Equal-Weight |
| 01/07/2022 | 318.08% | Morgan Stanley | $48 → $37 | Maintains | Equal-Weight |
| 12/08/2021 | 408.47% | Piper Sandler | → $45 | Upgrades | Neutral → Overweight |
| 11/03/2021 | 521.47% | Wells Fargo | $56 → $55 | Maintains | Equal-Weight |
| 08/04/2021 | 498.87% | Canaccord Genuity | $65 → $53 | Maintains | Buy |
| 04/01/2021 | 577.97% | Citigroup | → $60 | Initiates Coverage On | → Buy |
| 03/25/2021 | 464.97% | Piper Sandler | → $50 | Initiates Coverage On | → Neutral |
| 03/10/2021 | 713.56% | B of A Securities | → $72 | Upgrades | Neutral → Buy |
| 03/03/2021 | 634.46% | Canaccord Genuity | $49 → $65 | Maintains | Buy |
| 03/03/2021 | 498.87% | Morgan Stanley | $52 → $53 | Maintains | Equal-Weight |
| 12/15/2020 | 487.57% | Morgan Stanley | $46 → $52 | Maintains | Equal-Weight |
| 11/11/2020 | 419.77% | Morgan Stanley | $44 → $46 | Maintains | Equal-Weight |
| 10/26/2020 | 464.97% | B of A Securities | → $50 | Initiates Coverage On | → Buy |
| 10/26/2020 | 453.67% | Canaccord Genuity | → $49 | Initiates Coverage On | → Buy |
| 10/26/2020 | 464.97% | Stifel | → $50 | Initiates Coverage On | → Buy |
| 10/26/2020 | 397.18% | Morgan Stanley | → $44 | Initiates Coverage On | → Equal-Weight |
| 10/26/2020 | 419.77% | Wells Fargo | → $46 | Initiates Coverage On | → Equal-Weight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年10月31日 | 35.59% | 卡纳科特·格纳奇 | $20→$12 | 维护 | 买 |
| 09/05/2023 | 103.39% | 克雷格-哈勒姆 | →$18 | 开始承保 | →购买 |
| 08/03/2023 | 92.09% | 派珀·桑德勒 | $15→$17 | 维护 | 超重 |
| 07/11/2023 | 80.79% | 花旗集团 | $14→$16 | 维护 | 买 |
| 05/03/2023 | 58.19% | 花旗集团 | $13→$14 | 维护 | 买 |
| 05/03/2023 | 69.49% | 派珀·桑德勒 | $13→$15 | 维护 | 超重 |
| 05/03/2023 | 58.19% | 摩根士丹利 | $11→$14 | 维护 | 等重 |
| 04/03/2023 | 46.89% | 花旗集团 | $12→$13 | 维护 | 买 |
| 02/27/2023 | 69.49% | 富国银行 | $10→$15 | 升级 | 等重→超重 |
| 02/24/2023 | 35.59% | 花旗集团 | $10→$12 | 维护 | 买 |
| 02/23/2023 | 125.99% | 卡纳科特·格纳奇 | $18→$20 | 维护 | 买 |
| 02/23/2023 | 24.29% | 摩根士丹利 | $9.5→$11 | 维护 | 等重 |
| 01/06/2023 | 7.34% | 摩根士丹利 | $14→$9.5 | 维护 | 等重 |
| 01/03/2023 | -9.6% | B of A证券 | →$8 | 评级下调 | 中性→表现不佳 |
| 2022年12月12日 | -32.2% | 富国银行 | $13.5→$6 | 维护 | 等重 |
| 2022年12月12日 | 12.99% | 花旗集团 | $14→$10 | 升级 | 中性→购买 |
| 11/07/2022 | 58.19% | 摩根士丹利 | $19→$14 | 维护 | 等重 |
| 11/04/2022 | 46.89% | 派珀·桑德勒 | $25→$13 | 维护 | 超重 |
| 2022年10月11日 | 114.69% | 摩根士丹利 | $21→$19 | 维护 | 等重 |
| 08/04/2022 | 137.29% | 摩根士丹利 | $19→$21 | 维护 | 等重 |
| 08/03/2022 | 182.49% | 派珀·桑德勒 | $37→$25 | 维护 | 超重 |
| 07/18/2022 | 125.99% | Stifel | $32→$20 | 维护 | 买 |
| 07/15/2022 | 114.69% | 摩根士丹利 | $30→$19 | 维护 | 等重 |
| 07/11/2022 | 114.69% | 花旗集团 | $23→$19 | 评级下调 | 购买→中性 |
| 2022/05/17 | 159.89% | 花旗集团 | $32→$23 | 维护 | 买 |
| 02/25/2022 | 238.98% | 摩根士丹利 | $37→$30 | 维护 | 等重 |
| 02/24/2022 | 205.08% | 富国银行 | $55→$27 | 维护 | 等重 |
| 01/07/2022 | 318.08% | 摩根士丹利 | $48→$37 | 维护 | 等重 |
| 12/08/2021 | 408.47% | 派珀·桑德勒 | →$45 | 升级 | 中性→超重 |
| 11/03/2021 | 521.47% | 富国银行 | $56→$55 | 维护 | 等重 |
| 08/04/2021 | 498.87% | 卡纳科特·格纳奇 | $65→$53 | 维护 | 买 |
| 04/01/2021 | 577.97% | 花旗集团 | →$60 | 开始承保 | →购买 |
| 03/25/2021 | 464.97% | 派珀·桑德勒 | →$50 | 开始承保 | →中性 |
| 03/10/2021 | 713.56% | B of A证券 | →$72 | 升级 | 中性→购买 |
| 03/03/2021 | 634.46% | 卡纳科特·格纳奇 | $49→$65 | 维护 | 买 |
| 03/03/2021 | 498.87% | 摩根士丹利 | $52→$53 | 维护 | 等重 |
| 12/15/2020 | 487.57% | 摩根士丹利 | $46→$52 | 维护 | 等重 |
| 11/11/2020 | 419.77% | 摩根士丹利 | $44→$46 | 维护 | 等重 |
| 10/26/2020 | 464.97% | B of A证券 | →$50 | 开始承保 | →购买 |
| 10/26/2020 | 453.67% | 卡纳科特·格纳奇 | →$49 | 开始承保 | →购买 |
| 10/26/2020 | 464.97% | Stifel | →$50 | 开始承保 | →购买 |
| 10/26/2020 | 397.18% | 摩根士丹利 | →$44 | 开始承保 | →等重 |
| 10/26/2020 | 419.77% | 富国银行 | →$46 | 开始承保 | →等重 |
What is the target price for Pulmonx (LUNG)?
Pulmonx(肺)的目标价格是多少？
The latest price target for Pulmonx (NASDAQ: LUNG) was reported by Canaccord Genuity on October 31, 2023. The analyst firm set a price target for $12.00 expecting LUNG to rise to within 12 months (a possible 35.59% upside). 18 analyst firms have reported ratings in the last year.
Canaccel Genuity于2023年10月31日报道了Pulmonx(纳斯达克代码：LONG)的最新目标价。这家分析公司将目标价定为12.00美元，预计肺脏将在12个月内上涨(可能上涨35.59%)。去年有18家分析公司公布了评级。
What is the most recent analyst rating for Pulmonx (LUNG)?
分析师对Pulmonx(肺)的最新评级是多少？
The latest analyst rating for Pulmonx (NASDAQ: LUNG) was provided by Canaccord Genuity, and Pulmonx maintained their buy rating.
对Pulmonx(纳斯达克代码：LONG)的最新分析师评级由CANACCORD GENINITY提供，Pulmonx维持买入评级。
When is the next analyst rating going to be posted or updated for Pulmonx (LUNG)?
下一次分析师对Pulmonx(肺)的评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pulmonx, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pulmonx was filed on October 31, 2023 so you should expect the next rating to be made available sometime around October 31, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Pulmonx的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Pulmonx的上一次评级是在2023年10月31日提交的，所以你应该预计下一次评级将在2024年10月31日左右的某个时候公布。
Is the Analyst Rating Pulmonx (LUNG) correct?
分析师对肺脏(肺)的评级正确吗？
While ratings are subjective and will change, the latest Pulmonx (LUNG) rating was a maintained with a price target of $20.00 to $12.00. The current price Pulmonx (LUNG) is trading at is $8.85, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的肺(肺)评级维持不变，目标价在20.00美元至12.00美元之间。目前Pulmonx(肺)的交易价格为8.85美元，超出了分析师的预测区间。